Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HS336, intended for the treatment of advanced solid tumors.
HS336: A Novel SHP2 Inhibitor for Anti-Tumor Therapy
HS336 is a small molecule inhibitor of SHP2, a protein that plays a crucial role in tumor growth. The drug works by locking SHP2 in its self-inhibitory conformation, preventing the interaction between the PTP catalytic center and the substrate, which in turn exerts anti-tumor effects. HS336 is under development for the treatment of various advanced solid tumors, including esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and colorectal cancer.
Global Interest in SHP2 Inhibitors for Advanced Solid Tumors
Despite no such product being approved worldwide, there is significant interest in SHP2 inhibitors for the treatment of advanced solid tumors. Companies like Novartis, AbbVie, Jacobio Pharma, InnoCare Pharma, and Genhouse bio are actively involved in this field. Notably, Novartis’s TNO155 was the first SHP2 inhibitor to enter clinical trials globally, and Jacobio’s JAB-3068 holds the most advanced position in China.-Fineline Info & Tech
